Study #2026-0179
A Phase 1 Study Of LNK001 (dual ENPP3/CAIX AND-gate CAR T cell therapy) In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Fludarabine, LNK001
Description
There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC. The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clear Cell Renal Cell Carcinoma
Study phase:
Phase I
Physician name:
Samer Srour
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.